Patents by Inventor Kenji Morishima

Kenji Morishima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10763106
    Abstract: In one embodiment in which a technology which is capable of reducing voids that can occur when burying an insulating film into a trench while suppressing process complication, a method MT for processing a wafer W is provided. The wafer W has a groove 62 formed on the main surface 61 of the wafer W. The method MT includes: step S1 of accommodating the wafer W in a processing chamber 4 of a plasma processing apparatus 10; step S2 of starting supplying a first gas into the processing chamber 4; step S3 of starting supplying plasma generation high-frequency power into the processing chamber 4; and step S4 of starting intermittent supplying a second gas into the processing chamber 4 and starting supplying a third gas into the processing chamber 4 together, the first gas is a nitrogen-containing gas, the second gas is a gas that does not contain halogen, and the third gas is a gas that contains halogen.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: September 1, 2020
    Assignee: TOKYO ELECTRON LIMITED
    Inventors: Kenji Ouchi, Masato Morishima
  • Publication number: 20190189437
    Abstract: In one embodiment in which a technology which is capable of reducing voids that can occur when burying an insulating film into a trench while suppressing process complication, a method MT for processing a wafer W is provided. The wafer W has a groove 62 formed on the main surface 61 of the wafer W. The method MT includes: step S1 of accommodating the wafer W in a processing chamber 4 of a plasma processing apparatus 10; step S2 of starting supplying a first gas into the processing chamber 4; step S3 of starting supplying plasma generation high-frequency power into the processing chamber 4; and step S4 of starting intermittent supplying a second gas into the processing chamber 4 and starting supplying a third gas into the processing chamber 4 together, the first gas is a nitrogen-containing gas, the second gas is a gas that does not contain halogen, and the third gas is a gas that contains halogen.
    Type: Application
    Filed: June 15, 2017
    Publication date: June 20, 2019
    Applicant: TOKYO ELECTRON LIMITED
    Inventors: Kenji OUCHI, Masato MORISHIMA
  • Publication number: 20180353518
    Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicants: Santen Pharmaceutical Co., LTD., Asahi Glass Company, Limited
    Inventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
  • Publication number: 20160106757
    Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITED
    Inventors: Kenji MORISHIMA, Akio KIMURA, Hiroyuki ASADA, Masayuki UMEDA, Mitsuaki KUWANO
  • Publication number: 20070248697
    Abstract: A method of preventing a lowering of concentration of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? isopropyl ester, the prostaglandin derivative being contained in an ophthalmic solution as an active ingredient. The method including (i) adding to the ophthalmic solution a nonionic surfactant to inhibit the prostaglandin derivative from being adsorbed to a container which contains the ophthalmic solution, the container being made of a resin and (ii) adding to the ophthalmic solution an antioxidant to inhibit decomposition of the prostaglandin derivative.
    Type: Application
    Filed: June 26, 2007
    Publication date: October 25, 2007
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITED
    Inventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
  • Patent number: 7147844
    Abstract: A purpose of the present invention is to remove dryness and unpleasantness in eyes of contact lens wearers and to obtain favorable moist feel and wearing feel by stabilizing a lacrimal fluid layer on the surface of eyeballs of the wearers. By using an ophthalmic composition containing polyvinyl pyrrolidone, the lacrimal fluid layer existing on ionic contact lenses can be stabilized via adsorption of polyvinyl pyrrolidone on the ionic contact lenses. By adding a viscosity-increasing agent to the ophthalmic composition, the lacrimal fluid layer can be maintained in a stable state over a long period of time.
    Type: Grant
    Filed: December 26, 2000
    Date of Patent: December 12, 2006
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Takashi Hamano, Kenji Morishima, Norihisa Hatano
  • Publication number: 20050119299
    Abstract: Additives which enhance the antiseptic effect of a cationic antiseptic agent are added to ophthalmic solutions containing a compound having the chemical structure of the following general formula (I). The antimicrobial effect of the ophthalmic solutions containing a compound having the chemical structure of the general formula (I) and a cationic antiseptic agent is markedly increased by adding a basic amine compound to the solutions. In the general formula (I), R1 is a group of the following structural formula (Ia), (Ib), (Ic), (Id), (Ie) or (If).
    Type: Application
    Filed: September 2, 2004
    Publication date: June 2, 2005
    Applicant: SANKYO COMPANY, LIMITED
    Inventors: Takeshi Uneda, Akio Kimura, Kenji Morishima
  • Publication number: 20050106265
    Abstract: A method of preserving an aqueous liquid preparation comprising adding a preservative comprising boric acid and/or borax, ethylenediaminetetraacetic acid or a salt thereof and polyvinyl pyrrolidone, and optionally a cellulosic polymer to an aqueous liquid preparation.
    Type: Application
    Filed: December 13, 2004
    Publication date: May 19, 2005
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Morishima, Norihisa Hatano
  • Publication number: 20040097592
    Abstract: An object of the present invention is to formulate prostaglandin derivatives which are hardly soluble in water and liable to be adsorbed to a resinous container and prostaglandin derivatives which are liable to decompose when dissolved in water in ophthalmic solutions. Solubility of the prostaglandin derivatives in water is improved and the adsorption thereof to the resinous container can be remarkably inhibited by adding a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 to the ophthalmic solutions. The decomposition of the prostaglandin derivatives can be remarkably inhibited by adding an antioxidant such as disodium ethylenediaminetetraacetate or dibutylhydroxytoluene.
    Type: Application
    Filed: March 12, 2003
    Publication date: May 20, 2004
    Inventors: Kenji Morishima, Akio Kimura, Hiroyuki Asada, Masayuki Umeda, Mitsuaki Kuwano
  • Publication number: 20030152631
    Abstract: An object of the present invention is to provide safe preservatives by combining components widely used as additives of aqueous liquids. Preferred preservatives are obtained by combining boric acid and/or borax, ethylenediaminetetraacetic acid or a salt thereof and polyvinyl pyrrolidone. Preservation effects can be enhanced by further combining cellulosic polymers with the preservatives.
    Type: Application
    Filed: December 16, 2002
    Publication date: August 14, 2003
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kenji Morishima, Norihisa Hatano
  • Publication number: 20030021829
    Abstract: A purpose of the present invention is to remove dryness and unpleasantness in eyes of contact lens wearers and to obtain favorable moist feel and wearing feel by stabilizing a lacrimal fluid layer on the surface of eyeballs of the wearers. By using an ophthalmic composition containing polyvinyl pyrrolidone, the lacrimal fluid layer existing on ionic contact lenses can be stabilized via adsorption of polyvinyl pyrrolidone on the ionic contact lenses. By adding a viscosity-increasing agent to the ophthalmic composition, the lacrimal fluid layer can be maintained in a stable state over a long period of time.
    Type: Application
    Filed: June 24, 2002
    Publication date: January 30, 2003
    Inventors: Takashi Hamano, Kenji Morishima, Norihisa Hatano
  • Patent number: 6288049
    Abstract: A fluorometholone ophthalmic suspension containing fluorometholone as an active ingredient, wherein a cellulosic polymer, such as hydroxypropylmethylcellulose or methylcellulose, and a nonionic surfactant, such as polysorbate 80, are added thereto to increase the redispersibility of the fluorometholone. The amount of the cellulosic polymer is preferably 0.0001 to 0.003 (W/V) %, and the amount of the nonionic surfactant is preferably 0.0001 to 0.5 (W/V) %. The fluorometholone ophthalmic suspension has excellent redispersibility and hardly forms aggregates.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: September 11, 2001
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Morishima, Kazufumi Shiotani